Market news

U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.

Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with mixed price-target changes.

Editas Medicine (EDIT) has an average rating of overweight and mean price target of $4.88, according

Editas Medicine (NASDAQ:EDIT) outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol. Speaking at the Cantor Healthcare Conference, President and Chief Executive

Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O’Neill said during a Wells Fargo discussion. O’Ne

CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company’s newly appointed Chief Medical Officer, Daniel Ory, M.D. In connection with Dr. Ory’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. Ory as an inducement material to Dr. Ory entering into employment with Editas

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September: Wells Fargo Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, September 8Time: 4:30 p.m. ET Location: Boston, MA 2026 Cantor Global Healthcare ConferenceFormat: Fireside Chat Date: Thursday

Editas Medicine (EDIT) filed a registration statement Monday with the US Securities and Exchange Com

Editas Medicine (EDIT) has an average rating of overweight and mean price target of $6, according to

Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.

Detailed price information for Editas Medicine (EDIT-Q) from The Globe and Mail including charting and trades.

Editas (EDIT) delivered earnings and revenue surprises of +50.00% and +524.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a) and ApoB with EDIT-401 in non-human primates Recent financing strengthens Company’s capital position, supporting continued advancement of EDIT-401 program, with cash runway into the second half of 2028 CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasd

Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic Patrick T. Ellinor, M.D., Ph.D. Editas Medicine today announced the appointment of Patrick T. Ellinor, M.D., Ph.D., to its Board of Directors, effective August 6, 2026. CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing co